Opsona Therapeutics Ltd. Initiates a Prospective Open Label Phase I/II Study in Second-Line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS) with OPN-305, a First-in Class Monoclonal Antibody That Blocks To